surmount-1 tirzepatide weight loss percent nejm 2022 for Obesity: Highlights from the Trial Tirzepatide vs. Semaglutide for Patients
Description
FDA-approved tirzepatide (Zepbound and Mounjaro) remains the standard treatment option
Im on week 3 absolutely no problems
You and your provider should decide together what is good for your specific situation
Tracking your changes with a journal or health app can help you and your clinician see patterns and adjust if needed
Complete semaglutide dosage chart The standard semaglutide escalation schedule was established through the STEP clinical trial program for obesity (using the 2.4 mg target dose marketed as Wegovy) and through earlier trials for type 2 diabetes management (using the 2.0 mg maximum dose marketed as Ozempic)
